290 related articles for article (PubMed ID: 25370707)
1. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
6. VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.
Schultze A; Ben Batalla I; Riethdorf S; Bubenheim M; Yekebas E; Erbersdobler A; Reichelt U; Effenberger KE; Schmidt T; Izbicki JR; Bokemeyer C; Pantel K; Fiedler W; Loges S
Clin Exp Metastasis; 2012 Dec; 29(8):879-87. PubMed ID: 22484977
[TBL] [Abstract][Full Text] [Related]
7. Placenta growth factor (PlGF) mRNA expression in brain tumors.
Nomura M; Yamagishi S; Harada S; Yamashima T; Yamashita J; Yamamoto H
J Neurooncol; 1998 Nov; 40(2):123-30. PubMed ID: 9892094
[TBL] [Abstract][Full Text] [Related]
8. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
Valter MM; Hügel A; Huang HJ; Cavenee WK; Wiestler OD; Pietsch T; Wernert N
Cancer Res; 1999 Nov; 59(21):5608-14. PubMed ID: 10554042
[TBL] [Abstract][Full Text] [Related]
9. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
[TBL] [Abstract][Full Text] [Related]
10. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.
Pagani E; Ruffini F; Antonini Cappellini GC; Scoppola A; Fortes C; Marchetti P; Graziani G; D'Atri S; Lacal PM
Int J Oncol; 2016 Apr; 48(4):1581-9. PubMed ID: 26846845
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
Lombardi G; Zustovich F; Farina P; Polo V; Farina M; Della Puppa A; Bertorelle R; Gardiman MP; Berti F; Zagonel V
Anticancer Drugs; 2012 Aug; 23(7):749-53. PubMed ID: 22382388
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
Gabrusiewicz K; Liu D; Cortes-Santiago N; Hossain MB; Conrad CA; Aldape KD; Fuller GN; Marini FC; Alonso MM; Idoate MA; Gilbert MR; Fueyo J; Gomez-Manzano C
Oncotarget; 2014 Apr; 5(8):2208-20. PubMed ID: 24809734
[TBL] [Abstract][Full Text] [Related]
14. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer.
Maae E; Olsen DA; Steffensen KD; Jakobsen EH; Brandslund I; Sørensen FB; Jakobsen A
Breast Cancer Res Treat; 2012 May; 133(1):257-65. PubMed ID: 22270936
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.
Burger MC; Mildenberger IC; Wagner M; Mittelbronn M; Steinbach JP; Bähr O
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353668
[TBL] [Abstract][Full Text] [Related]
19. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.
Plate KH; Breier G; Farrell CL; Risau W
Lab Invest; 1992 Oct; 67(4):529-34. PubMed ID: 1434531
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.
Okamoto S; Nitta M; Maruyama T; Sawada T; Komori T; Okada Y; Muragaki Y
Brain Tumor Pathol; 2016 Apr; 33(2):129-36. PubMed ID: 26826105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
